Tectonic Therapeutic (TECX) CFO purchases 6,000 shares in open-market trade

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. Chief Financial Officer Daniel Lochner reported an open-market purchase of 6,000 shares of the company’s common stock on February 10, 2026, at a weighted average price of $21.61 per share. Following this transaction, he directly beneficially owns 32,044 common shares.

The purchase price reflects multiple trades executed in a range from $21.24 to $21.82 per share, as disclosed in the footnote. This filing documents increased personal share ownership by a senior executive through market purchases.

Insider Trade Summary

Net Buyer: 6,000 shares ($129,660)

Net Buy 1 txn

Insider Lochner Daniel

Role Chief Financial Officer

Bought 6,000 shs ($130K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	6,000	$21.61	$130K

Holdings After Transaction: Common Stock — 32,044 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lochner Daniel

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		P		6,000	A	$21.61(1)	32,044	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.24 to $21.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Daniel Lochner	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tectonic Therapeutic (TECX) disclose in this Form 4?

Tectonic Therapeutic disclosed that its Chief Financial Officer, Daniel Lochner, bought 6,000 shares of common stock in the open market. The weighted average purchase price was $21.61 per share, documenting an increase in his directly held ownership stake.

Who is the insider involved in the latest TECX Form 4 filing?

The insider is Daniel Lochner, Chief Financial Officer of Tectonic Therapeutic, Inc. He is identified as an officer, not a director or 10% owner, and this Form 4 reports his open-market purchase of additional common shares in the company.

How many Tectonic Therapeutic (TECX) shares did the CFO purchase and at what price?

The CFO purchased 6,000 shares of Tectonic Therapeutic common stock at a weighted average price of $21.61 per share. The filing notes these were multiple trades executed within a price range of $21.24 to $21.82 per share.

What is the CFO’s total Tectonic Therapeutic (TECX) ownership after this transaction?

After this transaction, Chief Financial Officer Daniel Lochner beneficially owns 32,044 shares of Tectonic Therapeutic common stock directly. This total reflects his holdings immediately following the reported 6,000-share open-market purchase on February 10, 2026.

Was the TECX insider transaction a purchase or a sale of shares?

The transaction was a purchase of common stock. The Form 4 uses transaction code “P,” indicating an open-market or private purchase, and explicitly classifies the activity as an acquisition of 6,000 shares rather than a sale or disposition.